MA39779A - Formulations de facteur ix lyophilisées - Google Patents

Formulations de facteur ix lyophilisées

Info

Publication number
MA39779A
MA39779A MA039779A MA39779A MA39779A MA 39779 A MA39779 A MA 39779A MA 039779 A MA039779 A MA 039779A MA 39779 A MA39779 A MA 39779A MA 39779 A MA39779 A MA 39779A
Authority
MA
Morocco
Prior art keywords
fix
polypeptide
formulations
present
factor
Prior art date
Application number
MA039779A
Other languages
English (en)
Inventor
Brandon W Leveille
Cherie Parkhurst-Lang
Brian M Thome
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA39779A publication Critical patent/MA39779A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Monitoring And Testing Of Transmission In General (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

La présente invention concerne, entre autres, des formulations de pré-lyophilisation, des formulations reconstituées, et des compositions de poudre de lyophilat comprenant un polypeptide du facteur ix (fix). La présente invention concerne également des procédés de lyophilisation pour la production de poudre de lyophilat comprenant un polypeptide fix. La présente invention concerne une formulation de pré-lyophilisation comprenant : (a) un polypeptide du facteur ix (fix) ayant une activité de coagulation fix ; (b) un agent tampon ; (c) un agent stabilisant ; (d) un agent gonflant ; et (e) un tensioactif, la formulation ayant un volume de remplissage inférieur à environ 5 ml, et chacun de (a) - (e) étant au niveau d'une quantité par flacon (mg/flacon) suffisante pour permettre (1) une meilleure stabilité du polypeptide fix lorsqu'elle est lyophilisée.
MA039779A 2014-03-24 2015-03-24 Formulations de facteur ix lyophilisées MA39779A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24

Publications (1)

Publication Number Publication Date
MA39779A true MA39779A (fr) 2017-02-01

Family

ID=54196282

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039779A MA39779A (fr) 2014-03-24 2015-03-24 Formulations de facteur ix lyophilisées

Country Status (16)

Country Link
US (3) US10772942B2 (fr)
EP (1) EP3123090A4 (fr)
JP (4) JP7058940B2 (fr)
KR (1) KR102385372B1 (fr)
AR (1) AR099838A1 (fr)
AU (3) AU2015236340B2 (fr)
CA (1) CA2943034C (fr)
CL (1) CL2016002386A1 (fr)
EA (2) EA202092926A3 (fr)
IL (3) IL247869B (fr)
MA (1) MA39779A (fr)
MX (2) MX387269B (fr)
PH (1) PH12016501877A1 (fr)
SG (3) SG10201913735SA (fr)
TW (1) TWI700101B (fr)
WO (1) WO2015148444A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144549A1 (fr) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Préparations contenant un polypeptide du facteur ix
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
MX2019006444A (es) * 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2019014338A1 (fr) * 2017-07-11 2019-01-17 Universal Stabilization Technologies, Inc. Procédé de conservation de produits biopharmaceutiques
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
BR112022015272A2 (pt) 2020-02-04 2022-09-20 Regeneron Pharma Teor de umidade residual alvo para produto de fármaco liofilizado
US20210395325A1 (en) * 2020-05-11 2021-12-23 Alkermes Pharma Ireland Limited Il-2 fusion polypeptide compositions and methods of making and using the same
CN118557531B (zh) * 2024-08-02 2024-10-18 成都蓉生药业有限责任公司 一种重组人凝血因子VIII-Fc融合蛋白冻干制剂的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2124690C (fr) 1992-10-02 2007-09-11 Thomas Osterberg Composition contenant une preparation du facteur de coagulation viii, methode de preparation et utilisation d'un surfactant comme stabilisateur
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (fr) * 1996-10-16 2000-09-09 Alza Corp
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
CA2383144A1 (fr) 1999-09-17 2001-03-29 Takeda Chemical Industries, Ltd. Procede de production d'une poudre proteique
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2002040544A2 (fr) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Facteur ix humain mutant a resistance accrue a l'inhibition par l'heparine
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
WO2006029467A1 (fr) * 2004-09-16 2006-03-23 Btf Pty Ltd Traitement de lyophylisation rapide
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005317166B2 (en) 2004-12-15 2009-09-10 Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
WO2007044616A2 (fr) * 2005-10-06 2007-04-19 Xencor, Inc. Anticorps anti-cd30 optimises
PL1942868T5 (pl) * 2005-11-01 2023-12-27 Wyeth Llc Roztwór chlorku sodu do odtwarzania lub rozcieńczania leku
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
TWI428448B (zh) 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
EP2423307A1 (fr) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Polypeptides du facteur IV à coagulation modifiée et leur utilisation pour le traitement
US8015841B2 (en) * 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
BRPI0821591A2 (pt) 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
NZ603997A (en) 2007-12-27 2013-02-22 Baxter Int Chemically Modified Factor IX
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
SG189790A1 (en) 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
DK2280734T3 (da) 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
CA2729972C (fr) 2008-08-05 2018-11-20 Wyeth Llc Lyophilisation au-dessus de la temperature d'effondrement
MX2011003074A (es) 2008-09-24 2011-04-19 Stabilitech Ltd Metodo para conservar polipeptidos utilizando un azucar y polietilenimina.
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
EP2458990B1 (fr) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Procédés de production de formulations pharmaceutiques lyophilisées à concentration élevée
PL3552619T3 (pl) * 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
EP2623497B1 (fr) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Sel de méglumine de 6-fluoro-3-hydroxy-2-pyrazine carboxamide
JP6125436B2 (ja) 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
WO2013185113A1 (fr) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Composés pro-coagulants
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
WO2014144549A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Préparations contenant un polypeptide du facteur ix
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations

Also Published As

Publication number Publication date
CA2943034A1 (fr) 2015-10-01
TW201605492A (zh) 2016-02-16
EA202092926A3 (ru) 2021-10-29
US20170173122A1 (en) 2017-06-22
MX387269B (es) 2025-03-18
JP7058940B2 (ja) 2022-04-25
IL247869B (en) 2020-02-27
KR102385372B1 (ko) 2022-04-11
JP2017510585A (ja) 2017-04-13
AU2015236340B2 (en) 2020-02-06
IL247869A0 (en) 2016-11-30
AU2020202863A1 (en) 2020-05-21
JP2020063313A (ja) 2020-04-23
AU2022215218B2 (en) 2025-12-18
WO2015148444A1 (fr) 2015-10-01
JP7503583B2 (ja) 2024-06-20
CL2016002386A1 (es) 2017-06-23
IL272257A (en) 2020-02-27
EA202092926A2 (ru) 2021-07-30
AU2020202863B2 (en) 2022-09-01
US20210069307A1 (en) 2021-03-11
SG10201808249VA (en) 2018-10-30
IL281197A (en) 2021-04-29
KR20160137577A (ko) 2016-11-30
AU2022215218A1 (en) 2022-09-01
BR112016021777A2 (pt) 2017-10-03
NZ724351A (en) 2023-10-27
JP2022044689A (ja) 2022-03-17
JP2024053015A (ja) 2024-04-12
EA201691807A1 (ru) 2017-03-31
SG10201913735SA (en) 2020-03-30
IL281197B (en) 2022-06-01
US12128092B2 (en) 2024-10-29
EP3123090A1 (fr) 2017-02-01
PH12016501877A1 (en) 2016-12-19
TWI700101B (zh) 2020-08-01
JP7759978B2 (ja) 2025-10-24
MX2021012939A (es) 2021-11-25
AR099838A1 (es) 2016-08-24
EA038573B1 (ru) 2021-09-16
CA2943034C (fr) 2022-06-14
IL272257B (en) 2021-03-25
EP3123090A4 (fr) 2017-12-13
AU2015236340A1 (en) 2016-09-29
US10772942B2 (en) 2020-09-15
SG11201607642RA (en) 2016-10-28
US20250121042A1 (en) 2025-04-17
MX2016012447A (es) 2017-01-06

Similar Documents

Publication Publication Date Title
MX2021012939A (es) Formulaciones de factor ix liofilizadas.
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2020009878A (es) Composiciones farmaceuticas en polvo seco estables al calor y metodos.
EP4360652A3 (fr) Formulations de virus adéno-associés
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
WO2015058173A8 (fr) Unités solides stables et leurs procédés de préparation
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
MY206306A (en) Stable semaglutide compositions and uses thereof
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
PH12018500458A1 (en) Vlp stabilized vaccine compositions
PH12018500675A1 (en) Stable live attenuated recombinant dengue vaccine
TW200630118A (en) Stabilized freeze-dried formulation for cephalosporin derivatives
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
HK1234139A1 (en) Lyophilized factor ix formulations
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
EA201390206A1 (ru) Составы для бычьего гранулоцитарного колониестимулирующего фактора и его вариантов
GR1008818B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου